爱博医疗：公司“全视”多焦人工晶状体产品的营业收入占比正在持续提升

Core Viewpoint - The announcement from the National Organization for High-Value Medical Consumables Joint Procurement Office on October 29 indicates the disqualification of Carl Zeiss Medical Technology (Germany) GmbH's bifocal astigmatism lenses, creating a market gap that other brands, such as Aibo Medical, may fill [1] Group 1: Company Developments - Aibo Medical (688050.SH) reported on November 5 that the revenue share of its "All-View" multifocal intraocular lens products is continuously increasing [1] - The company emphasizes its technological advantages, which have established a good reputation among doctors and patients [1] - Aibo Medical plans to actively seize market opportunities to further enhance its product market share [1]